Neuren Pharmaceuticals completed their Phase II clinical trial for testing the drug NNZ-2591 in Phelan-McDermid syndrome. Neuren has released a statement that the drug was found to be generally safe and well tolerated.

They are also announcing positive results in communication, behavior, cognition/learning, and socialization.

The Phelan-McDermid Syndrome Foundation (PMSF) led the travel reimbursement program for this study, and is proud to have been involved in making the trial accessible to families. PMSF meets regularly with Neuren and other pharmaceutical companies to lower barriers to clinical trials, stay updated on behalf of the community, and amplify families’ voices. This news represents significant progress for drug development in Phelan-McDermid syndrome.

You may view more information on Neuren’s website at this link: https://www.neurenpharma.com/pdf/17dad47d-e6b6-44fa-8633-d65e2270420c/Investor-presentation-18-December-2023.pdf for more information on the study and the drug which was tested.

Thank you to all our families who participated!!